Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043671 | 0.83 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL12000529 | 0.83 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL15042373 | 0.81 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL10179262 | 0.76 | SLC6A3 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3516295 | 0.76 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL15042359 | 0.74 | SLC6A3 (0.39) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15863260 | 0.74 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL15873672 | 0.74 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL15042438 | 0.73 | SLC6A4 (0.33) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15042320 | 0.73 | SLC6A3 (0.46) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | SLC6A4 2698/4885SLC6A3 2766/4885SLC6A2 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.